Halozyme Therapeutics
HALO
New Fortress Energy
NFE
DexCom
DXCM
4
YETI Holdings
YETI
5
Teradata Corp
TDC
US Stock MarketDetailed Quotes
JANX Janux Therapeutics
- 25.700
- +0.160+0.63%
Close May 7 16:00 ET
- 25.080
- -0.620-2.41%
Pre 04:29 ET
1.52BMarket Cap-20.08P/E (TTM)
26.400High24.800Low1.56MVolume25.620Open25.540Pre Close39.89MTurnover4.17%Turnover RatioLossP/E (Static)59.11MShares71.71052wk High1.49P/B961.52MFloat Cap22.52052wk Low--Dividend TTM37.41MShs Float71.710Historical High--Div YieldTTM6.27%Amplitude5.650Historical Low25.598Avg Price1Lot Size
Janux Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 13.37%-43.81M | -68.92%-16.73M | 80.95%-2.23M | 33.43%-10.02M | -6.66%-14.84M | -17.83%-50.58M | 16.89%-9.9M | 12.71%-11.71M | -147.88%-15.05M | -20.73%-13.91M |
| Net income from continuing operations | -18.36%-68.99M | -71.93%-20.22M | -142.56%-28.06M | 65.96%-5.96M | 15.46%-14.76M | 7.56%-58.29M | 26.81%-11.76M | 30.71%-11.57M | -3.67%-17.51M | -30.19%-17.46M |
| Depreciation and amortization | 5.37%2.06M | -3.58%512K | 2.00%510K | 7.43%506K | 17.44%532K | 132.46%1.96M | 31.76%531K | 100.80%500K | 336.11%471K | 459.26%453K |
| Change In working capital | 110.45%685K | 68.52%-345K | 516.39%12.83M | -338.40%-7.35M | -535.29%-4.45M | -253.27%-6.55M | -231.10%-1.1M | -287.55%-3.08M | -126.36%-1.68M | 67.09%-700K |
| -Change in receivables | ---- | ---- | ---- | -1,030.80%-6.98M | 30.80%-519K | ---- | ---- | ---- | --750K | ---750K |
| -Change in prepaid assets | -1,661.90%-3.28M | -175.19%-203K | -127.17%-144K | 21.30%-1.76M | -171.01%-1.17M | 106.23%210K | 433.33%270K | 140.74%530K | -281.43%-2.24M | 217.79%1.65M |
| -Change in payables and accrued expense | 1,598.75%6.01M | -109.96%-75K | 426.78%5.75M | 86.01%2.37M | -204.20%-2.03M | -110.38%-401K | -38.68%753K | -178.07%-1.76M | 3,537.84%1.27M | -259.57%-667K |
| -Change in other current assets | 66.49%-375K | 68.72%-61K | -253.78%-183K | 85.89%-116K | 93.21%-15K | 11.89%-1.12M | 37.70%-195K | 110.42%119K | -732.31%-822K | -501.82%-221K |
| -Change in other working capital | 68.15%-1.67M | 99.69%-6K | 95.33%-92K | -34.64%-859K | -0.28%-713K | -203.78%-5.24M | -286.35%-1.92M | -1,777.14%-1.97M | -109.31%-638K | 40.75%-711K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 13.37%-43.81M | -68.92%-16.73M | 80.95%-2.23M | 33.43%-10.02M | -6.66%-14.84M | -17.83%-50.58M | 16.89%-9.9M | 12.71%-11.71M | -147.88%-15.05M | -20.73%-13.91M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -526.36%-258.02M | 205.01%33.93M | 120.62%12.67M | -1,167.95%-190.89M | -1,201.33%-113.74M | -170.70%-41.19M | 793.45%11.12M | -410.94%-61.45M | 97.74%17.87M | -128.13%-8.74M |
| Net PPE purchase and sale | 80.59%-359K | 91.84%-42K | 94.68%-25K | 83.62%-95K | 30.88%-197K | 71.30%-1.85M | 74.95%-515K | 81.35%-470K | 35.41%-580K | 70.65%-285K |
| Net investment purchase and sale | -554.90%-257.66M | 191.87%33.97M | 120.82%12.7M | -1,133.87%-190.79M | -1,242.86%-113.54M | -160.80%-39.34M | 2,474.78%11.64M | -373.67%-60.98M | 85.71%18.45M | -126.39%-8.46M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -526.36%-258.02M | 205.01%33.93M | 120.62%12.67M | -1,167.95%-190.89M | -1,201.33%-113.74M | -170.70%-41.19M | 793.45%11.12M | -410.94%-61.45M | 97.74%17.87M | -128.13%-8.74M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 1,097.75%713.24M | 46,428.28%386.65M | -97.09%1.65M | 423.67%2.77M | 20,290.57%322.17M | 11,809.60%59.55M | 335.08%831K | 56.61M | 71.43%528K | 157,900.00%1.58M |
| Net common stock issuance | 1,135.21%698.27M | --378.21M | --0 | ---455K | --320.51M | --56.53M | --0 | --56.53M | --0 | --0 |
| Proceeds from stock option exercised by employees | 395.96%14.97M | 915.88%8.44M | 1,987.34%1.65M | 509.85%3.22M | 4.87%1.66M | 503.60%3.02M | 335.08%831K | --79K | 71.43%528K | 157,900.00%1.58M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 1,097.75%713.24M | 46,428.28%386.65M | -97.09%1.65M | 423.67%2.77M | 20,290.57%322.17M | 11,809.60%59.55M | 335.08%831K | --56.61M | 71.43%528K | 157,900.00%1.58M |
| Net cash flow | ||||||||||
| Beginning cash position | -61.68%20.02M | 53.44%27.57M | -55.16%15.48M | 585.31%213.62M | -61.68%20.02M | 43.53%52.24M | -72.60%17.97M | -41.71%34.52M | -44.28%31.17M | 43.53%52.24M |
| Current changes in cash | 1,376.81%411.4M | 19,571.26%403.85M | 173.06%12.09M | -6,018.19%-198.14M | 1,018.79%193.6M | -303.36%-32.22M | 115.41%2.05M | -360.69%-16.55M | 2.26%3.35M | -207.80%-21.07M |
| End cash Position | 2,054.84%431.42M | 2,054.84%431.42M | 53.44%27.57M | -55.16%15.48M | 585.31%213.62M | -61.68%20.02M | -61.68%20.02M | -72.60%17.97M | -41.71%34.52M | -44.28%31.17M |
| Free cash flow | 15.74%-44.17M | -60.97%-16.77M | 81.48%-2.26M | 35.29%-10.12M | -5.90%-15.03M | -6.19%-52.43M | 25.43%-10.42M | 23.57%-12.18M | -124.27%-15.63M | -13.63%-14.2M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025